Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

35.160
-1.380-3.78%
Volume:599.60K
Turnover:20.91M
Market Cap:8.69B
PE:273.17
High:35.500
Open:34.520
Low:34.400
Close:36.540
52wk High:53.450
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:0.17
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.129
ROE:0.82%
ROA:-0.80%
PB:1.49
PE(LYR):273.17
PS:6.01

Loading ...

Dual-Listed Stock Premium Ranking: August 14 Market Close

Stock News
·
Aug 14

CANSINOBIO Reports Zero Share Capital Changes for July 2026; 860,000 H-Share Options Remain Outstanding

Bulletin Express
·
Aug 04

AH Share Premium and Deviation Data for July 20th

Stock News
·
Jul 20

CANSINOBIO Shares Surge on Regulatory Progress for Meningitis Vaccine

Stock News
·
Jul 20

CanSino Biologics Gets NMPA Nod to Review Supplemental Application Expanding Menhycia® Age Range

Bulletin Express
·
Jul 19

CansinoBIO Receives NMPA Acceptance for Age Extension of MenQuad Vaccine

Stock News
·
Jul 19

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13

CANSINOBIO Sees Stable Share Capital in June 2026; Public Float Meets HKEX Requirement

Bulletin Express
·
Jul 03

AH Share Premium and Deviation Rankings for July 3rd

Stock News
·
Jul 03

CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Argentina

MT Newswires Live
·
Jun 25

CanSino Biologics: MCV4 Vaccine Gains Argentine Registration, Advancing Global Strategy

Bulletin Express
·
Jun 25

CansinoBIO Secures Regulatory Approval in Argentina for Meningococcal Vaccine

Stock News
·
Jun 25

CanSino Biologics Defines Governance, Capital Structure and Dividend Policy in Updated Articles of Association

Bulletin Express
·
Jun 10

CANSINOBIO Keeps Share Capital Steady in May; 2.91 Million Shares Reserved for Incentive Plans

Bulletin Express
·
Jun 02

CanSino Biologics Begins Trials of Broad Pneumococcal Conjugate Vaccine

MT Newswires Live
·
May 26

CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled

Stock News
·
May 26

CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express
·
May 26

CANSINOBIO Sets 2025 AGM for 10 June 2026; Seeks Share-Issuance, Repurchase and Dividend Mandates

Bulletin Express
·
May 19

CANSINOBIO Calls 10 June 2026 AGM to Approve 2025 Results, No Dividend Payout, and Fresh Financing Mandates

Bulletin Express
·
May 19

CanSino Biologics' Drug Application for Combined Vaccines Granted Priority Review in China

MT Newswires Live
·
May 11